Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Joshua

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
Seminars in Oncology Nursing|July 2, 2025
Development and Validation of a Patient-Reported Outcome Measure to Assess the Impact of Steroids in the Treatment of Myeloma: The Steroid Symptom Questionnaire-Multiple MyelomaTracy King, Louise Acret, Claudia Rutherford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myelomaConstantine S Mitsiades, Faith E Davies, Jacob P Laubach, et al.
Leukemia & Lymphoma|July 20, 2013
Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive stateJames Favaloro, Ross Brown, Esther Aklilu, et al.
Blood|June 19, 2012
CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells to T cells and are associated with poor prognosisRoss Brown, Karieshma Kabani, James Favaloro, et al.
Leukemia & Lymphoma|February 18, 2014
Excellent outcomes for adolescents and adults with acute lymphoblastic leukemia and lymphoma without allogeneic stem cell transplant: the FRALLE-93 pediatric protocolJay Hocking, Anthony P Schwarer, Robin Gasiorowski, et al.
Leukemia & Lymphoma|February 5, 2015
Using digital polymerase chain reaction to detect minimal residual disease in myeloma by identifying FGFR3 up-regulationSimon McAuliffe, Ross Brown, Alberto Catalano, et al.
Leukemia & Lymphoma|March 15, 2014
Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myelomaJames Favaloro, Tulita Liyadipitiya, Ross Brown, et al.
Internal Medicine Journal|November 28, 2022
Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory GroupDipti Talaulikar, Douglas Joshua, Phoebe Joy Ho, et al.
Leukemia & Lymphoma|September 23, 2017
Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR studyHartmut Goldschmidt, Philippe Moreau, Heinz Ludwig, et al.
British Journal of Clinical Pharmacology|February 17, 2016
High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantationChrista E Nath, Judith Trotman, Campbell Tiley, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Seminars in Oncology Nursing|July 2, 2025
Development and Validation of a Patient-Reported Outcome Measure to Assess the Impact of Steroids in the Treatment of Myeloma: The Steroid Symptom Questionnaire-Multiple MyelomaTracy King, Louise Acret, Claudia Rutherford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myelomaConstantine S Mitsiades, Faith E Davies, Jacob P Laubach, et al.
Leukemia & Lymphoma|July 20, 2013
Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive stateJames Favaloro, Ross Brown, Esther Aklilu, et al.
Blood|June 19, 2012
CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells to T cells and are associated with poor prognosisRoss Brown, Karieshma Kabani, James Favaloro, et al.
Leukemia & Lymphoma|February 18, 2014
Excellent outcomes for adolescents and adults with acute lymphoblastic leukemia and lymphoma without allogeneic stem cell transplant: the FRALLE-93 pediatric protocolJay Hocking, Anthony P Schwarer, Robin Gasiorowski, et al.
Leukemia & Lymphoma|February 5, 2015
Using digital polymerase chain reaction to detect minimal residual disease in myeloma by identifying FGFR3 up-regulationSimon McAuliffe, Ross Brown, Alberto Catalano, et al.
Leukemia & Lymphoma|March 15, 2014
Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myelomaJames Favaloro, Tulita Liyadipitiya, Ross Brown, et al.
Internal Medicine Journal|November 28, 2022
Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory GroupDipti Talaulikar, Douglas Joshua, Phoebe Joy Ho, et al.
Leukemia & Lymphoma|September 23, 2017
Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR studyHartmut Goldschmidt, Philippe Moreau, Heinz Ludwig, et al.
British Journal of Clinical Pharmacology|February 17, 2016
High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantationChrista E Nath, Judith Trotman, Campbell Tiley, et al.
Pageof 5